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A b s t r a c t
High-resolution melting analysis (HRMA) provides 
a valid approach to efficiently detect DNA genetic 
and somatic mutations. In this study, HRMA was used 
for the screening of 116 colorectal cancers (CRCs) 
to detect hot-spot mutations in the KRAS and BRAF 
oncogenes. Mutational hot spots on the PIK3CA gene, 
exons 9 and 20, were also screened. Direct sequencing 
was used to confirm and characterize HRMA results. 
HRMA revealed abnormal melting profiles in 65 CRCs 
(56.0%), 16 of them harboring mutations in 2 different 
genes simultaneously. The frequency of mutations 
was 17.2% for PIK3CA (11.2% in exon 9 and 6.0% 
in exon 20), 43.1% for KRAS exon 2, and 9.5% in 
exon 15 of the BRAF gene. We found a significant 
association between PIK3CA and KRAS mutations (P 
= .008), whereas KRAS and BRAF mutations were 
mutually exclusive (P = .001). This report describes a 
novel approach for the detection of PIK3CA somatic 
mutations by HRMA.
The request for rapid and reliable mutation screening 
in human cancers is rapidly increasing for the definition 
of clinical samples and orienting targeted therapies. High-
resolution melting analysis (HRMA) was recently proposed 
as a very sensitive scanning method that allows rapid detec-
tion of DNA sequence variations without cumbersome 
post–polymerase chain reaction (PCR) methods.1-3 Mutation 
scanning with HRMA is based on the dissociation behavior 
of DNA when exposed to an increasing temperature. Signal 
modification is generated from the transition from a double 
to single strand in the presence of fluorescent dyes actively 
intercalating double-stranded DNA.4 The HRMA melting 
profile gives a specific sequence-related pattern allowing 
discrimination between wild-type sequences and homozy-
gote-heterozygote variants.5 Applications of HRMA have 
been described for the identification of germline and somat-
ic mutations.6-11 Owing to its high sensitivity, HRMA seems 
to represent a more sensitive approach to detect a minimal 
fraction of mutated cells in tumoral tissue that, in many 
cases, is not achievable by direct sequencing.
In the present study, we used HRMA for the rapid and 
sensitive detection of somatic mutations in hot-spot regions of 
3 oncogenes (KRAS, BRAF, and PIK3CA) that are frequently 
mutated in colorectal cancer (CRC).
RAS proteins belong to an effector family that regulates 
intracellular signaling pathways involved in proliferation, 
survival, and differentiation.12 Cancer-associated mutations 
responsible for gain-of-function of RAS genes have been 
described in non–small cell lung cancer,13-15 in the biliary 
tract,12 and in pancreas.12 Missense RAS mutations essentially 
cause substitutions at codons 12, 13, and 61, transforming the 
intrinsic GTPase activity of the protein in the constitutively 
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active conformation. In CRC, KRAS mutations occur in 
30% to 51% of cases12,16-18 and are inversely associated 
with BRAF mutations, suggesting that their involvement in 
cancer progression can independently induce similar cellular 
effects through the same pathway.16 Recently, HRMA was 
proposed for use in screening for KRAS mutations in human 
lung cancer.15
BRAF is a cytosolic protein kinase and is activated by 
membrane-bound RAS. Mutated BRAF activates a signaling 
cascade involving proteins in the mitogen-activated protein 
kinase system, resulting in cell proliferation.19 BRAF muta-
tions occur in about 10% of CRCs, with the most common 
mutation being the T to A transversion at nucleotide 1796, 
causing V600E. This mutation predisposes to inhibition 
of apoptosis, increases invasiveness,20 and occurs earlier 
during colorectal carcinogenesis.21 The BRAF V600E muta-
tion is mutually exclusive with KRAS mutations and is sig-
nificantly associated with microsatellite instability, resulting 
from aberrant methylation of the MLH1 promoter.22 HRMA 
has been previously proposed for use in screening for BRAF 
mutations in human melanoma.23
We also performed HRMA to identify hot-spot gain-of-
function mutations in exons 9 and 20 in PIK3CA, the cata-
lytic subunit of phosphatidylinositol 3-kinase (PI3K). PI3Ks 
are heterodimeric kinases involved in the control of cel-
lular growth, transformation, adhesion, and apoptosis.24-26 
Somatic mutations of PIK3CA were described in CRCs with 
a frequency ranging from 13.6% to 32%.24,25,27,28 In CRCs, 
3 mutational hot spots were described (E542K, E545K, and 
H1047R), covering about 80% of all PIK3CA mutations.24 
The first two are located in the helical domain, and the third 
is in the C-terminal region of the protein.26,28 These gain-
of-function mutations confer strong oncogenicity as shown 
by in vivo29 and in vitro assays.30 Recently, a significant 
correlation between PIK3CA mutations and patient survival 
was found in CRC,28 suggesting that screening for PIK3CA 
mutations could be useful in the selection of patients for 
adjuvant therapy.
Materials and Methods
Samples
Tissue samples were obtained from 116 consecutive 
patients with sporadic CRC (60 men and 56 women; age 
range, 43-89 years; mean, 65.8 years). Informed consent 
was obtained from all patients. Samples were snap frozen 
and stored in liquid nitrogen until analysis. Tumor histologic 
type and grade of differentiation were defined according to 
the World Health Organization criteria31 and staged accord-
ing to the American Joint Committee on Cancer TNM 
staging system.32 DNA extraction was performed by using 
BIOROBOT EZ1 (QIAGEN, Milan, Italy) and the EZ1 
DNA Tissue Kit (QIAGEN) according to the manufacturer’s 
protocol.
Cell Lines
Positive control samples were obtained from DNA 
of cell lines harboring mutations in the target genes, as 
reported by Ikediobi et al.33 SW620 and HCT116 were used 
as reference for KRAS codon 12 (G12V, homozygous) and 
13 (G13D, heterozygous) mutations, respectively; for exons 
9 and 20 of PIK3CA, we used MCF-7 (E545K, heterozy-
gous) and HCT116 (H1047R, heterozygous), respectively. 
SK-MEL-28 (V600E, homozygous) and MDA-MB-231 
(G464V, heterozygous) were the references for exons 11 and 
15 of the BRAF gene. DNA was extracted from cell lines by 
using the QIAamp DNA Mini Kit (QIAGEN).
High-Resolution Melting Analysis
For HRMA, 100 ng of DNA was amplified in a 
final volume of 10 µL by using the following: 1.25 µL 
of PCR Buffer (Applied Biosystems, Monza, Italy), 1.5 
mmol/L of magnesium chloride (Applied Biosystems), 
300 nmol/L of each primer, 1.5 µmol/L of SYTO9 
Dye (Invitrogen, Carlsbad, CA), and 1.25 U of Taq 
Gold Polymerase (Applied Biosystems). PCR was 
submitted in a 9700 GeneAmp PCR system (Applied 
Biosystems) thermal cycler to an initial denaturation at 
95°C for 10 minutes followed by 35 cycles of 1 min-
ute at 95°C, 1 minute at 60°C, and 1 minute at 72°C 
and a final extension at 72°C for 15 minutes. For the 
HRMA melting profile, performed on the RotorGene 
6000 (Corbett Research, Sydney, Australia), samples 
were denatured with an initial hold of 5 minutes at 
95°C and 1 minute at 40°C and a melting profile from 
75°C to 85°C for KRAS and BRAF; 77°C to 87°C for 
PIK3CA exon 20 and 70°C to 85°C for PIK3CA exon 9, 
with a ramping degree of 0.05°C. Primers for HRMA analysis 
were selected using Primer3 software34 and were as follows: 
KRAS, 59-GCCTGCTGAAAATGACTGAA-39 (forward), 
59-AGAATGGTCCTGCACCAGTAA-39 (reverse); PIK3CA 
exon 9, 59-CTAGCTAGAGACAATGAATTAAGGGAAA-
39 (forward), 59-CATTTTAGCACTTACCTGTGACTCCA-
39 (reverse); PIK3CA exon 20, 59-TGAGCAAGAGGCTTT 
GGAGT-39 (forward), 59-TCATTTTCTCAGTTATC 
TTTTCAGTTCAAT-39 (reverse). Screening for BRAF gene 
exons 11 and 15 was performed as previously reported.23
DNA Sequencing
To confirm HRMA results, sequencing analysis was also 
performed in all samples. After HRMA, samples were purified 
with a PCR Purification Kit (QIAGEN) and submitted to cycle 
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sequencing with 2 µL of BigDye Terminator Ready Reaction 
Mix (Applied Biosystems) and the same primers used in 
HRMA but 0.8 µmol/L in a final volume of 10 µL. After 
purification with a DyeEx 2.0 Spin Kit (QIAGEN), samples 
were analyzed with the ABI Prism 310 Genetic Analyzer 
(Applied Biosystems).
Statistical Analysis
Statistical analysis was carried out using the SPSS soft-
ware package (SPSS, Chicago, IL). Statistical differences 
between groups were assessed by using the χ2 test, consid-
ering the P value as obtained by using the Fisher exact test. 
Differences with a P value of less than .05 were considered 
statistically significant.
Results
Reliability and Sensitivity of HRMA
Sensitivity of the melting profile in discriminating dif-
ferent percentages of mutated alleles was initially evaluated 
by using serial dilutions of mutated DNA, derived from 
cultured cell lines, variably mixed with wild-type DNA, 
obtained from wild-type cell lines. We tested 100%, 75%, 
50%, 25%, 15%, 10%, and 5% (mutated/wild type) dilutions 
of SW620 (mutated in codon 12 of KRAS) and SK-MEL-28 
cell lines (mutated in exon 15 of BRAF), both carrying the 
respective mutation in homozygosis. Our results confirmed 
that the technique can detect at least 5% of mutated alleles 
(data not shown). For MCF-7 (PIK3CA in exon 9) and 
HCT-116 (PIK3CA in exon 20) that contain mutations in 
heterozygosis, samples were diluted at 50%, 25%, 12%, 6%, 
and 3% ❚Figure 1❚. We were able to identify the presence of 
an abnormal profile of HRMA in all dilutions, allowing the 
clear identification of mutated alleles (Figure 1).
HRMA and Sequencing Analysis
Examples of HRMA and melting profiles obtained from 
CRCs carrying mutations of KRAS and BRAF are shown in 
❚Figure 2❚. HRMA profiles of exons 9 and 20 of PIK3CA, 
with direct comparison of sequencing results, are shown in 
❚Figure 3❚ and ❚Figure 4❚, respectively. A clear definition of 
the presence of somatic mutations in a sample was achiev-
able by the comparison of the profile with wild-type DNA. 
Sequencing analysis was performed in all samples using the 
same PCR products after melting analysis. In all cases, dide-
oxy sequencing confirmed the results of HRMA.
We found at least 1 mutation in 65 (56.0%) of 116 cases, 
with 16 of them harboring 2 mutations simultaneously. Nine 
variants in the KRAS gene were detected with a 43.1% global 
frequency ❚Table 1❚. Among them, the G12D substitution 
was the most prevalent (42%). In our cases we also detected 
uncommon KRAS mutations: 1 case with Q22K mutation and 1 
case with L19F, recently described as an activating mutation.35 
In 1 case, HRMA and sequencing analysis identified an 
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❚Figure 1❚ Difference plots generated with serial dilutions of DNA from mutated cell lines with wild-type (wt) DNA to assess 
high-resolution melting analysis sensitivities. A, PIK3CA exon 9 mutation detected using MCF-7 DNA. B, PIK3CA exon 20 
mutation detected by HCT116. Percentages of relative amount of mutated allele are also reported.
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additional variant: an in-frame c.30_31insGGA insertion 
(Figure 2A) resulting in a glycine insertion (p.10_11insG) 
that has not been reported before in CRC. This mutation 
was previously described only in 1 case of childhood 
myeloid leukemia and was tested for its activating fea-
tures.36 In the BRAF gene, no mutation was found in exon 
11, whereas the final frequency of the V600E mutation in 
exon 15 was 9.5%.
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❚Figure 2❚ High-resolution melting analysis of KRAS (A) and BRAF exon 15 (B). Arrows indicate wild-type (wt) control and 
colorectal cancer samples with somatic mutations.
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❚Figure 3❚ High-resolution melting analysis of PIK3CA exon 9. A, Melting profiles with arrows that indicate wild-type (wt) control 
and colorectal cancer samples with somatic mutations. Inset, Difference plots of mutated samples normalized against wt DNA, 
B, Electropherograms of sequencing analysis in the same samples.
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For the PIK3CA gene, among the 7 variants we identi-
fied, E545K, E542K, and H1047R were confirmed as the 
most frequent mutations for exons 9 and 20 (15/20 [75%]). 
The final frequency of hot-spot mutations involving PIK3CA 
was 20 (17.3%) of 116 (Table 1).
Τhe analysis of our results confirmed that KRAS and 
BRAF mutations are mutually exclusive (P = .001) because 
none of the 50 CRCs with KRAS mutations had a concomitant 
mutation in BRAF. On the contrary, PIK3CA and KRAS cor-
related significantly (P = .008) because 14 (70%) of 20 CRCs 
carrying 1 mutation in the PIK3CA gene had also 1 mutation 
in the KRAS gene. In particular, all PIK3CA mutants in exon 
20 (n = 7) are concomitant with KRAS mutations, whereas 
only 7 (54%) of 13 of exon 9 mutants are associated with 
KRAS mutations. In 2 (10%) of 20 CRCs with PIK3CA exon 
9 mutations, a BRAF mutation was also present.
Discussion
The main purpose of this study was to develop a sensi-
tive test that allows rapid identification of hot-spot mutations 
in PIK3CA, KRAS, and BRAF oncogenes in CRC. In recent 
years, the research and clinical management of CRC have 
❚Table 1❚
Number of Variants Detected by High-Resolution Melting 
Analysis and Defined by Direct Sequencing for the KRAS, 
BRAF, and PIK3CA Genes
Gene/Nucleotide Protein  No. of Relative Total 
Change Mutation Samples  %  %*
KRAS    
   c.35G>A G12D 21 42 18.1
   c.35G>T G12V 8 16 6.9
   c.38G>A G13D 7 14 6.0
   c.34G>T G12C 6 12 5.2
   c.35G>C G12A 4 8 3.4
   c.34G>C G12R 1 2 0.9
   c.57G>T L19F 1 2 0.9
   c.64C>A Q22K 1 2 0.9
   c.30_31insGGA p.10_11insG  1 2 0.9
   Total  50 100 43.1
BRAF    
   c.1799T>A V600E 11 100 9.5
PIK3CA    
   Exon 9    
      c.1633G>A E545K 6 30 5.2
      c.1624G>A E542K 4 20 3.4
      c.1637A>T Q546L 2 10 1.7
      c.1636C>G Q546E 1 5 0.9
   Exon 20    
      c.3140A>G H1047R 5 25 4.3
      c.3129G>T M1043I 1 5 0.9
      c.3127A>G M1043V 1 5 0.9
   Total  20 100 17.3
* Of 116 cases.
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❚Figure 4❚ High-resolution melting analysis of PIK3CA exon 20. A, Melting profiles with arrows that indicate wild-type (wt) 
control and colorectal cancer samples with somatic mutations. Inset, Difference plots of mutated samples normalized against 
wt DNA. B, Electropherograms of sequencing analysis in the same samples.
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changed and been revised on the basis of genetic features that 
characterize this tumor.17,37 The involvement of independent 
pathways in the carcinogenesis of CRC is supported by the 
existence of great variability in the pattern of somatic muta-
tions. Further investigations should be performed to clarify 
the clinical role of single or multiple somatic mutations, and 
it is then reasonable to insist on the development of achiev-
able genetic tests to facilitate patient stratification for targeted 
therapeutic approaches. Therefore, rapid detection of multiple 
mutations with high accuracy in a series of known oncogenes 
will be more often requested in future clinical management.
In a mutational study on 1,000 human tumor samples, 
Thomas et al38 confirmed that changes affecting a small 
number of codons often account for the majority of somatic 
mutations. In the same adapted high-throughput genotyp-
ing, the authors also demonstrated that PIK3CA, KRAS, and 
BRAF genes could be regarded as colorectal-specific somatic 
mutations.38 Even if it is widely accepted that some oncogene 
mutations occur in a mutually exclusive or inclusive manner, 
it remains to be clarified when and where they can really inter-
fere with common pathways. Controversial data are reported 
on the correlation between PIK3CA and KRAS mutations, 
and it is still unclear whether mutations that affect both genes 
could effectively influence the phenotypic features of the 
tumor. In a recent study, KRAS and PIK3CA mutations were 
reported to be not correlated in CRC,28 whereas, according to 
the study by Thomas et al,38 about 30% of PIK3CA somatic 
mutations couple with another oncogene mutation, mainly 
represented by the KRAS gene. Our data indicate that in 14 
(70%) of 20 CRCs with a PIK3CA mutation, there was a con-
comitant mutation in KRAS (P = .008). In particular, 100% of 
cases with PIK3CA mutations in exon 20 were simultaneously 
mutated in KRAS, whereas only 54% of CRCs carrying an 
exon 9 mutant shared a mutation with KRAS. Finally, our data 
confirmed that mutations in BRAF were mutually exclusive 
of KRAS mutations.
HRMA provides a reliable and cost-limited approach 
to perform genetic screenings in tumor samples. Our experi-
ments on reconstituted samples, obtained by serial dilutions of 
mutated cancer cell lines and normal DNA, indicated the pos-
sibility of identifying at least 5% of mutated alleles in a back-
ground of wild-type DNA. This theoretical sensitivity seems 
well suited for detecting even a limited percentage of mutated 
alleles in a heterogeneous sample, as obtained from CRC ran-
dom tissue biopsies. The whole procedure seems very rapid, 
eliminating the need for cumbersome and technically demand-
ing prescreening tests. In addition, HRMA was demonstrated 
to be useful in the identification of rare KRAS mutations. We 
identified 1 case of an in-frame c.30_31insGGA insertion 
that was responsible for the insertion of an extra glycine. 
This insertion, even previously demonstrated in 1 infant with 
leukemia, has not been reported before in colorectal cancer. 
This mutation was reported to induce cell transformation 
in vitro and activation of the Ras-mitogen-activated protein 
kinase signaling pathway.36 This observation is in accordance 
with the finding that synthetic mutants with insertion of 
extra amino acids in the phosphate-binding P-loop of KRAS 
(codons 10-17) can induce a reduction of affinity for guanos-
ine 59-diphosphate, leading to a preference for guanosine 
59-triphosphate binding and promoting outgrowth comparable 
to single point KRAS mutants.39
Our results seem to point out the importance of new 
rapid and sensitive procedures for accurate screening for 
somatic mutations to detect common and rare oncogene 
mutants in CRCs. HRMA seems to be a relevant tool for 
this type of study.
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